Filing identity and reporting period
Important mismatch: The supplied filing is Vallon Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2022 (ticker VLON), not a GRI Bio, Inc. 10-K. It discusses a proposed merger with GRI Bio. This is an annual report, not a standalone 2022 fourth-quarter report.
Business context
Vallon was a clinical-stage biotechnology company developing abuse-deterrent CNS medicines. Its lead candidate ADAIR failed to meet the SEAL study’s primary endpoint in March 2022; ADMIR was also in development. Vallon reduced spending while evaluating strategic alternatives and signed a merger agreement with GRI Bio on December 13, 2022. The proposed combined company would focus on immune-related inflammatory, fibrotic, and autoimmune diseases.
Vallon had no approved products and no product-sales revenue. Its Medice license for European ADAIR rights provided a $0.1 million upfront payment in 2020, with potential milestones of up to $6.3 million and low-double-digit tiered royalties on net sales.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Research and development expense | $1.170 million | $5.187 million |
| General and administrative expense | $5.758 million | $4.072 million |
| Total operating expenses | $6.928 million | $9.259 million |
| Net loss | $7.024 million | $9.303 million |
| Net loss per share, basic and diluted | $0.69 | $1.42 |
| Cash used in operating activities | $7.135 million | $8.312 million |
| Cash and cash equivalents at year-end | $3.781 million | $3.702 million |
R&D expense fell by $4.0 million, principally because ADAIR development spending declined. G&A rose by $1.7 million, primarily due to strategic-review costs. 2022 cash flow also included $3.782 million provided by investing activities, mainly from marketable-security maturities, and $3.432 million provided by financing activities, mainly from the May 2022 offering. Year-end total assets were $4.152 million, total liabilities $1.810 million, and stockholders’ equity $2.342 million. Current assets exceeded current liabilities by $2.342 million.
Gross margin is not meaningful for this pre-commercial business; the filing does not provide a clear 2022 product-revenue figure in the supplied text. There was no marketable securities balance at year-end and no finance lease liability; $0.122 million of warrant liability remained. The filing reports accumulated deficit of $28.926 million and states that the auditor’s report includes substantial doubt about Vallon’s ability to continue as a going concern. Management estimated existing cash would fund operations for more than four months from the filing date, after current obligations.
Merger, outlook, and material risks
- The merger was pending when the report was filed. The parties targeted a second-quarter 2023 closing, subject to stockholder approvals, financing, Nasdaq listing conditions, and other closing requirements. The exchange ratio could change based on Vallon’s closing net cash and Nasdaq requirements.
- Vallon estimated approximately negative $3.5 million of net cash at closing if it occurred in Q2 2023. The agreement’s net-cash condition and potential Nasdaq valuation adjustment could materially affect the exchange ratio and dilution. Illustrative ownership estimates vary with assumptions; the filing’s fully diluted scenario shows the financing investor at approximately 84.7%.
- On February 21, 2023, Nasdaq granted a stay of delisting procedures through April 28, 2023, conditioned in part on completing the merger and meeting initial listing requirements by that date. Vallon had previously failed the $1.00 minimum-bid-price requirement and did not meet the stated $5.0 million stockholders’ equity requirement for a second compliance extension.
- If the merger failed, Vallon said it might pursue another transaction, seek asset partnerships or licensing, continue operations, or liquidate. Management warned that additional funding might not be available and that failure to obtain it could force curtailed operations, cessation, or bankruptcy.
- Estimated direct merger transaction costs were approximately $4.7 million, plus approximately $0.2 million of Vallon’s share of common expenses; further combined-company public-company costs were not estimated. A termination under specified circumstances could involve a $2.0 million fee and expense reimbursement up to $0.4 million.
- The proposed merger was expected to cause an ownership change that could limit use of tax attributes. Vallon reported federal, state, and local NOL carryforwards of $25.6 million, $25.9 million, and $18.6 million, respectively; the filing cautions that some may not be usable.
- Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor did not provide an internal-control attestation because of Vallon’s emerging-growth-company exemption.
Most important facts for investors to verify
- Confirm the issuer and filing: this document is Vallon’s 2022 10-K, not GRI Bio’s filing.
- Check subsequent filings for whether the merger and related equity financing closed, the final exchange ratio, reverse split, proceeds, and post-closing ownership and dilution.
- Verify Nasdaq listing status and whether all conditions attached to the April 28, 2023 stay were met.
- Assess the actual cash runway, transaction-related cash uses, and financing needs against the going-concern warning.
- Review the merger’s final costs, termination provisions, and any changes to the stated net-cash or listing conditions.